23,428 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Purchased by Landscape Capital Management L.L.C.

Landscape Capital Management L.L.C. acquired a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) during the 4th quarter, Holdings Channel.com reports. The fund acquired 23,428 shares of the biopharmaceutical company’s stock, valued at approximately $705,000.

Other large investors also recently bought and sold shares of the company. Blue Trust Inc. raised its position in shares of TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 371 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of TG Therapeutics by 512.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 1,594 shares during the period. Jones Financial Companies Lllp lifted its position in shares of TG Therapeutics by 460.7% in the 4th quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company’s stock worth $64,000 after buying an additional 1,737 shares during the last quarter. Synergy Asset Management LLC acquired a new position in shares of TG Therapeutics in the 4th quarter valued at about $75,000. Finally, GAMMA Investing LLC grew its position in shares of TG Therapeutics by 562.4% during the 4th quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company’s stock valued at $77,000 after buying an additional 2,171 shares during the last quarter. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Price Performance

Shares of NASDAQ TGTX opened at $37.35 on Monday. The stock has a market cap of $5.87 billion, a P/E ratio of -373.46 and a beta of 2.13. The firm’s 50-day simple moving average is $35.27 and its 200 day simple moving average is $30.89. TG Therapeutics, Inc. has a fifty-two week low of $12.93 and a fifty-two week high of $43.32. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm had revenue of $108.19 million for the quarter, compared to analysts’ expectations of $100.67 million. Equities analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 4th. HC Wainwright reiterated a “buy” rating and issued a $55.00 price objective on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, TG Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.